SHANGHAI, China, November 5, 2026, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the abstract of the research results of CT1190B (an allogeneic CAR T-cell product candidate targeting CD19/CD20) in the treatment of relapsed/refractory large B-cell lymphoma and the abstract of the research results of CT071 (an autologous CAR T-cell product candidate targeting GPRC5D) for the treatment of relapsed/refractory multiple myeloma (R/R MM) and high-risk newly diagnosed multiple myeloma (HR-NDMM) have been published at the 68th Annual Meeting of the American Society of Hematology (ASH). The data of both product candidates will be presented as poster presentations at the Annual Meeting of ASH. Updated research results of CT0596 (an allogeneic CAR T-cell product candidate targeting BCMA) in the treatment of R/R MM and primary plasma cell leukemia will be published in a separate announcement of the Company in December 2026.
?
Title?
Safety and efficacy of CT1190B, an allogeneic anti-CD19/CD20-CAR T-cell therapy, with modified lymphodepletion in relapsed or refractory large B cell lymphoma
?
Publication Number
4172
?
Poster Presentation Date & Time
December 13, 2026, 6:00 – 8:00 PM EST
?
Title
Efficacy, safety, and pharmacokinetics of GPRC5D-targeted CAR T-cell therapy in high-risk newly diagnosed multiple myeloma versus relapsed/refractory multiple myeloma: A comparative analysis of two phase I studies
?
Publication Number
5801
?
Poster Presentation Date & Time
December 14, 2026, 6:00 – 8:00 PM EST
?
About CT1190B
CT1190B is a CD19/CD20-targeted allogeneic CAR T-cell therapy developed based on CARsgen’s THANK-u Plus? platform. Registrational Phase I clinical trial for refractory/relapse large B-cell lymphoma is ongoing.
?
About CT071
CT071 is a CAR T-cell therapy candidate developed utilizing the proprietary CARcelerate? platform of CARsgen targeting GPRC5D for the treatment of relapsed/refractory multiple myeloma or relapsed/refractory plasma cell leukemia. An investigator-initiated trial (NCT05838131) is ongoing in China to evaluate the preliminary safety and efficacy of CT071 for the treatment of relapsed/refractory multiple myeloma or plasma cell leukemia. Another investigator-initiated trial (NCT06407947) is ongoing in China for the treatment of high-risk newly diagnosed multiple myeloma.
?
About CT0596
CT0596 is an allogeneic BCMA-targeted CAR T-cell therapy developed using CARsgen’s proprietary THANK-u Plus? platform. It is currently being evaluated in registrational Phase I trial for R/R MM. Previous IITs have shown that CT0596 demonstrated preliminary favorable tolerability and encouraging efficacy signals in R/R MM and primary plasma cell leukemia. Further investigation is planned in additional plasma cell malignancies and autoimmune diseases mediated by autoreactive plasma cells.
?
About CARsgen Therapeutics Holdings Limited
CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen’s mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable.
?
Forward-looking Statements
All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group’s current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group’s control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading “Principal Risks and Uncertainties” in our most recent annual report and interim report and other announcements and reports made available on our corporate website, . No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release.
?
Contact CARsgen
For more information, please visit /
Public Relations:?PR@carsgen.com?
Investor Relations:?IR@carsgen.com
?